To evaluate whether long-term magnetic resonance imaging (MRI) findings, alone or in combination with prostate-specific antigen (PSA) density or the result of prior surveillance biopsies, could be used to omit biopsies occurring after patients have been on active surveillance (AS) for ≥5 years.
